The short version of tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
=== The 1978 reconstitution === Following a number of episodes, the three 1962 representative bodies were replaced by four new associations in 1978, including the AGSI. The association moved quickly to place a pay claim, and has remained very active since. Its first general secretary was the secretary of the preceding body, Derek Nally, a sergeant from County Wexford, who was succeeded in 1983 by P.J. Rogan for a year. In 2021, two members of the National Executive raised questions about the accuracy of the AGSI accounts, and they, and then two more, resigned, and the organisation's trustees raised a formal query in their annual report. Although members of the NEC are elected from branches, the resignations were described as "human resources matters" by the AGSI president, as the association's leadership promoted constitutional changes. The accounts were signed off by the AGSI's auditors, and annual delegate conference. In 2023, during disputes with the Garda authorities over rosters for front-line Gardai, the AGSI declined to join the Garda Representative Association in their action.
=== Folk medicine === In myths and folk medicine, honey was used both orally and topically to treat various ailments including gastric disturbances, ulcers, skin wounds, and skin burns by ancient Greeks and Egyptians, and in Ayurveda and traditional Chinese medicine.
== Diseases == The house cricket was essentially eliminated from the cricket-breeding industries of North America and Europe by the appearance of cricket paralysis virus which spread rapidly in Europe in 2002 and then in the United States in 2010. The virus is extremely lethal to this species of cricket and a few others, and left many hobbyists and researchers without adequate feeder insects. It has been replaced by the Jamaican field cricket, which is resistant to cricket paralysis virus and has many of the desirable features of the house cricket.
Sources: en.wikipedia.org
== Post-translational modifications == Conjugated proteins are synthesized by post-translational modifications where additional chemical groups are attached to the protein structure that has already been formed by a ribosome in a different biological process called translation. Modifications in conjugated proteins occur mainly because of specific enzymes. These modifications can happen in many different areas all around the cell. One form of a modification is glycosylation. Glycosylation is when carbohydrates are attached to proteins making glycoproteins. Glycosylation mostly happens in the endoplasmic reticulum and Golgi apparatus. Glycosylation aids in the folding of proteins, the stability, and in cell signaling. Another form of a modification is phosphorylation. Phosphorylation is when a kinase, a type of enzyme, adds a phosphate group to the protein. This process is reversible and the phosphate group can be removed from the protein when a phosphatase, another type of enzyme, is present. Phosphorylation plays an important role in the regulation of the activity of many different protein molecules. Metalloproteins also go through a modification to attach their metal ions. Similarly, hemoproteins also go through a post-translational modification to have their heme group attached to the protein.
=== Helmut Kohl === In October 1982 the SPD–FDP coalition fell apart when the FDP joined forces with the CDU/CSU to elect CDU Chairman Helmut Kohl as Chancellor in a constructive vote of no confidence. Following national elections in March 1983, Kohl emerged in firm control of both the government and the CDU. The CDU/CSU fell just short of an absolute majority, due to the entry into the Bundestag of the Greens, who received 5.6% of the vote. In January 1987 the Kohl–Genscher government was returned to office, but the FDP and the Greens gained at the expense of the larger parties. Kohl's CDU and its Bavarian sister party, the CSU, slipped from 48.8% of the vote in 1983 to 44.3%. The SPD fell to 37%; long-time SPD Chairman Brandt subsequently resigned in April 1987 and was succeeded by Hans-Jochen Vogel. The FDP's share rose from 7% to 9.1%, its best showing since 1980. The Greens' share rose to 8.3% from their 1983 share of 5.6%.
==== MeSH D12.776.964.700.045 – adenovirus early proteins ==== MeSH D12.776.964.700.045.050 – adenovirus e1 proteins MeSH D12.776.964.700.045.050.100 – adenovirus e1a proteins MeSH D12.776.964.700.045.050.110 – adenovirus e1b proteins MeSH D12.776.964.700.045.060 – adenovirus e2 proteins MeSH D12.776.964.700.045.070 – adenovirus e3 proteins MeSH D12.776.964.700.045.080 – adenovirus e4 proteins
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.